Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17331620 | 0.89 | PIK3CD (0.41) | LRRK2PIK3CDPIK3CGPIK3R2PIK3CB | |
| SCHEMBL17331681 | 0.86 | PIK3CD (0.44) | LRRK2PIK3CDPIK3CGPIK3R2PIK3CB | |
| SCHEMBL17331665 | 0.86 | PIK3CD (0.50) | LRRK2PIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL17331791 | 0.83 | PIK3CD (0.47) | LRRK2PIK3CDPIK3CGPIK3R2PIK3CB | |
| SCHEMBL17331829 | 0.80 | AURKA (0.36) | LRRK2PIK3CDRPS6KB1AURKA | |
| SCHEMBL21218879 | 0.74 | ADORA1 (0.42) | PIK3CDPIK3CB | |
| SCHEMBL17331781 | 0.72 | LRRK2 (0.44) | LRRK2PIK3CDPIK3CGPIK3CB | |
| SCHEMBL19322406 | 0.72 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL17397114 | 0.72 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CB | |
| SCHEMBL17331893 | 0.71 | PIK3CD (0.49) | LRRK2PIK3CDPIK3CGPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | claimed |
| EP-3157920-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2017-04-26 | — | — | EP | claimed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | claimed |
| WO-2015193263-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-23 | — | — | WO | claimed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | claimed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| EP-3157920-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2017-04-26 | — | — | EP | disclosed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| WO-2015193263-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193263-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | disclosed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIP4K2B, PIP5K1B, PIP4K2A | LRRK2 473/4885PIK3CD 15/4885PIK3CG 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.